Last 12 months
Inside the activity.
0 purchase rows · 279 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 31 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 111 |
| Feb 2026 | 0 | 11 |
| Mar 2026 | 0 | 106 |
| Apr 2026 | 0 | 14 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 18, 2018 Filed Nov 26, 2018 21:11 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000079 · edgardoc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 3,038 F2 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| October 18, 2018 Filed Jun 7, 2019 20:04 UTC |
Greene Barry EPresident
|
OtherCommon Stock | 21 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000046 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 2,905 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| October 18, 2018 Filed Jun 7, 2019 20:03 UTC |
Vaishnaw AkshayPresident, R&D
|
OtherCommon Stock | 21 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000045 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 416 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| October 18, 2018 Filed Jun 7, 2019 20:03 UTC |
KEATING LAURIEEVP, Chief Legal Officer
|
OtherCommon Stock | 14 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000044 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 334 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:59 UTC |
KEATING LAURIESVP, GC & Secretary
|
GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000076 · edgardoc.xml · derivative · entry 2 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:59 UTC |
KEATING LAURIESVP, GC & Secretary
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 3,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000076 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 3,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:58 UTC |
Greenstreet YvonneEVP, Chief Operating Officer
|
GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000075 · edgardoc.xml · derivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F1 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:57 UTC |
Vaishnaw AkshayPresident, R&D
|
GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000074 · edgardoc.xml · derivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:57 UTC |
Vaishnaw AkshayPresident, R&D
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 7,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000074 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:55 UTC |
Mason MichaelVP, Finance and Treasurer
|
GrantPerformance Stock Option 2016 (right to buy) · Derivative | 1,387 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000072 · edgardoc.xml · derivative · entry 2 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,775 Underlying: Common Stock · 1,387 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:55 UTC |
Mason MichaelVP, Finance and Treasurer
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 1,800 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000072 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,400 Underlying: Common Stock · 1,800 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:54 UTC |
Greene Barry EPresident
|
GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000071 · edgardoc.xml · derivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:54 UTC |
Greene Barry EPresident
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 10,000 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000071 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:56 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000073 · edgardoc.xml · derivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:56 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 16,250 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000073 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 16,250 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:15 UTC |
Greenstreet YvonneEVP, Chief Operating Officer
|
SaleCommon Stock | 2,500 | $120.00 | $300,000.00 |
DisclosureSEC source: 0001735276-18-000064 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,916 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 17, 2018. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:15 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 16,250 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000062 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 16,250 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:15 UTC |
Greene Barry EPresident
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 10,000 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000061 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:15 UTC |
Vaishnaw AkshayPresident, R&D
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 7,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000060 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:14 UTC |
KEATING LAURIESVP, GC & Secretary
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 3,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000059 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 3,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:13 UTC |
Mason MichaelVP, Finance and Treasurer
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 1,800 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000058 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 1,800 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:55 UTC |
Vaishnaw AkshayPresident, R&D
|
Tax withholdingCommon Stock | 766 | $90.95 | $69,667.70 |
DisclosureSEC source: 0001325812-18-000030 · primary_doc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,173 Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:55 UTC |
Vaishnaw AkshayPresident, R&D
|
GrantCommon Stock | 1,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000030 · primary_doc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,939 F1 · kind: On January 4, 2016, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. The shares subject to release vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the RSU shares have vested. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:21 UTC |
Greenstreet YvonneEVP, Chief Operating Officer
|
GrantPerformance Stock Option 2016 (right to buy) · Derivative | 25,000 | $0.00 Strike: $77.10 | $0.00 |
DisclosureSEC source: 0001735276-18-000051 · edgardoc.xml · derivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-09-19 F3 · kind: On September 19, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. The shares subject to the option will vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the option shares have vested. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:21 UTC |
Greenstreet YvonneEVP, Chief Operating Officer
|
Tax withholdingCommon Stock | 3,084 | $90.95 | $280,489.80 |
DisclosureSEC source: 0001735276-18-000051 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,416 Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:21 UTC |
Greenstreet YvonneEVP, Chief Operating Officer
|
GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000051 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · kind: On June 29, 2017, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. One half of the shares subject to release will vest upon the achievement of each of two specific commercial events as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the first performance criterion has been met and one half of the shares have vested. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:05 UTC |
KEATING LAURIESVP, GC & Secretary
|
Tax withholdingCommon Stock | 605 | $90.95 | $55,024.75 |
DisclosureSEC source: 0001735276-18-000050 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,258 Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:05 UTC |
KEATING LAURIESVP, GC & Secretary
|
GrantCommon Stock | 1,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000050 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,863 F1 · kind: On January 4, 2016, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. The shares subject to release vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the RSU shares have vested. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:00 UTC |
Mason MichaelVP, Finance and Treasurer
|
Tax withholdingCommon Stock | 449 | $90.95 | $40,836.55 |
DisclosureSEC source: 0001735276-18-000049 · edgardoc.xml · nonDerivative · entry 2 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563 Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:00 UTC |
Mason MichaelVP, Finance and Treasurer
|
GrantCommon Stock | 1,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000049 · edgardoc.xml · nonDerivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012 F1 · kind: On January 4, 2016, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. The shares subject to release vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the RSU shares have vested. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 21:54 UTC |
Soni Manmeet SinghChief Financial Officer
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 25,000 | $0.00 Strike: $52.61 | $0.00 |
DisclosureSEC source: 0001735276-18-000048 · edgardoc.xml · derivative · entry 6 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-08 F2 · kind: On May 8, 2017, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. The shares subject to the option will vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the option shares have vested. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 23:14 UTC |
Greene Barry EPresident
|
GrantPerformance Based Stock Option 2014 (right to buy) · Derivative | 15,875 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · derivative · entry 7 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,625 Underlying: Common Stock · 15,875 shares Expires 2024-12-17 F4 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 23:14 UTC |
Greene Barry EPresident
|
GrantPerformance Based Stock Option 2013 (right to buy) · Derivative | 15,000 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · derivative · entry 6 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires 2023-12-18 F3 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:55 UTC |
Vaishnaw AkshayPresident, R&D
|
GrantPerformance Based Stock Option 2014 (right to buy) · Derivative | 11,707 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001325812-18-000030 · primary_doc.xml · derivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,125 Underlying: Common Stock · 11,707 shares Expires 2024-12-17 F4 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:55 UTC |
Vaishnaw AkshayPresident, R&D
|
GrantPerformance Based Stock Option 2013 (right to buy) · Derivative | 10,832 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000030 · primary_doc.xml · derivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 10,832 shares Expires 2023-12-18 F3 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:33 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
GrantPerformance Based Stock Option 2014 (right to buy) · Derivative | 25,000 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001325812-18-000029 · primary_doc.xml · derivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2024-12-17 F2 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:33 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
GrantPerformance Based Stock Option 2013 (right to buy) · Derivative | 25,000 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000029 · primary_doc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 15,000 shares Expires 2023-12-18 F1 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:05 UTC |
KEATING LAURIESVP, GC & Secretary
|
GrantPerformance Stock Option 2014 (right to buy) · Derivative | 1,984 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001735276-18-000050 · edgardoc.xml · derivative · entry 4 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,958 Underlying: Common Stock · 1,984 shares Expires 2024-12-17 F3 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:00 UTC |
Mason MichaelVP, Finance and Treasurer
|
GrantPerformance Stock Option 2014 (right to buy) · Derivative | 2,750 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001735276-18-000049 · edgardoc.xml · derivative · entry 7 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2024-12-17 F4 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:00 UTC |
Mason MichaelVP, Finance and Treasurer
|
GrantPerformance Stock Option 2013 (right to buy) · Derivative | 1,666 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000049 · edgardoc.xml · derivative · entry 6 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,666 Underlying: Common Stock · 1,666 shares Expires 2023-12-18 F3 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award. Read SEC document |
| July 31, 2018 Filed Aug 14, 2018 23:14 UTC |
Greene Barry EPresident
|
GiftCommon Stock | 9,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · nonDerivative · entry 5 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 9,030 F2 · ownership.nature: The 9,030 shares were previously reported as directly beneficially owned. On 7/31/2018, the shares were contributed to the "Barry E. Greene Qualified Annuity Interest Trust" (GRAT). Barry E. Greene is the sole trustee. Read SEC document |
| July 31, 2018 Filed Aug 14, 2018 23:14 UTC |
Greene Barry EPresident
|
GiftCommon Stock | 9,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000031 · primary_doc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,938 Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · derivative · entry 9 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,636 Underlying: Common Stock · 50,000 shares Expires 2018-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F8 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 1,400 | $106.25 | $148,750.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 6 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,297 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F6 · price: Sale prices ranged from $106.18 to $106.33. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 34,995 | $105.83 | $3,703,520.85 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 5 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,697 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F5 · price: Sale prices ranged from $105.17 to $106.13. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 7,758 | $104.83 | $813,271.14 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,692 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F4 · price: Sale prices ranged from $104.17 to $105.15. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 3,847 | $103.69 | $398,895.43 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,450 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F3 · price: Sale prices ranged from $103.10 to $104.04. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 2,000 | $102.51 | $205,020.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,297 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F2 · price: Sale prices ranged from $101.99 to $102.94. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 50,000 | $21.35 | $1,067,500.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. Read SEC document |
| July 10, 2018 Filed Jul 27, 2018 20:07 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
OtherCommon Stock | 31 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 8 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 3,021 F7 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F7 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F7 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.